PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT

PART 03: RESEARCH METHODOLOGY

PART 04: MARKET LANDSCAPE
• Market ecosystem
• Market characteristics
• Market segmentation analysis

PART 05: MARKET SIZING
• Market definition
• Market sizing 2017
• Market size and forecast 2017-2022

PART 06: FIVE FORCES ANALYSIS
• Bargaining power of buyers
• Bargaining power of suppliers
• Threat of new entrants
• Threat of substitutes
• Threat of rivalry
• Market condition

PART 07: PIPELINE

PART 08: MARKET SEGMENTATION BY PRODUCT
• Segmentation by product
• Comparison by product
• Small molecules – Market size and forecast 2017-2022
• Biologics – Market size and forecast 2017-2022
• Market opportunity by product

PART 09: CUSTOMER LANDSCAPE

PART 10: REGIONAL LANDSCAPE
• Geographical segmentation
• Regional comparison
• Americas – Market size and forecast 2017-2022
• EMEA – Market size and forecast 2017-2022
• APAC – Market size and forecast 2017-2022
• Market opportunity

PART 11: DECISION FRAMEWORK

PART 12: DRIVERS AND CHALLENGES
• Market drivers
• Market challenges

PART 13: MARKET TRENDS
• Technological advances
• Increasing patient support programs
• Strategic alliances

PART 14: VENDOR LANDSCAPE
• Overview
• Landscape disruption

PART 15: VENDOR ANALYSIS
• Vendors covered
• Vendor classification
• Market positioning of vendors
• F. Hoffmann-La Roche
• Merck Sharp & Dohme
• Novartis
• Pfizer
• Spectrum Pharmaceuticals

PART 16: APPENDIX
• List of abbreviations

List of Exhibits
Exhibit 01: Parent market
Exhibit 02: Global NHL therapeutics market segmentation
Exhibit 03: Market characteristics
Exhibit 04: Market segments
Exhibit 05: Market definition - Inclusions and exclusions checklist
Exhibit 06: Market size 2017
Exhibit 07: Validation techniques employed for market sizing 2017
Exhibit 08: Global DLBCL therapeutics market – Market size and forecast 2017-2022 ($ mn)
Exhibit 09: Global DLBCL therapeutics market – Year-over-year growth 2018-2022 (%)
Exhibit 10: Five forces analysis 2017
Exhibit 11: Five forces analysis 2022
Exhibit 12: Bargaining power of buyers
Exhibit 13: Bargaining power of suppliers
Exhibit 14: Threat of new entrants
Exhibit 15: Threat of substitutes
Exhibit 16: Threat of rivalry
Exhibit 17: Market condition - Five forces 2017
Exhibit 18: Pipeline landscape by development phase 2017-2018
Exhibit 19: Late-stage pipeline molecules for treatment of DLBCL 2017-2018
Exhibit 20: Global DLBCL therapeutics market by product – Market share 2017-2022 (%)
Exhibit 21: Comparison by product
Exhibit 22: Global DLBCL therapeutics market by small molecules – Market size and forecast 2017-2022 ($ mn)
Exhibit 23: Global DLBCL therapeutics market by small molecules – Year-over-year growth 2018-2022 (%)
Exhibit 24: Global DLBCL therapeutics market by biologics – Market size and forecast 2017-2022 ($ mn)
Exhibit 25: Global DLBCL therapeutics market by biologics – Year-over-year growth 2018-2022 (%)
Exhibit 26: Market opportunity by product
Exhibit 27: Customer landscape
Exhibit 28: Global DLBCL therapeutics market – Market share by geography 2017-2022 (%)
Exhibit 29: Regional comparison
Exhibit 30: DLBCL therapeutics market in Americas – Market size and forecast 2017-2022 ($ mn)
Exhibit 31: DLBCL therapeutics market in Americas – Year-over-year growth 2018-2022 (%)
Exhibit 32: Top 3 countries in Americas
Exhibit 33: DLBCL therapeutics market in EMEA – Market size and forecast 2017-2022 ($ mn)
Exhibit 34: DLBCL therapeutics market in EMEA – Year-over-year growth 2018-2022 (%)
Exhibit 35: Top 3 countries in EMEA
Exhibit 36: DLBCL therapeutics market in APAC – Market size and forecast 2017-2022 ($ mn)
Exhibit 37: DLBCL therapeutics market in APAC – Year-over-year growth 2018-2022 (%)
Exhibit 38: Top 3 countries in APAC
Exhibit 39: Market opportunity
Exhibit 40: Vendor landscape
Exhibit 41: Landscape disruption
Exhibit 42: Vendors covered
Exhibit 43: Vendor classification
Exhibit 44: Market positioning of vendors
Exhibit 45: F. Hoffmann-La Roche – Overview
Exhibit 46: F. Hoffmann-La Roche – Business segments
Exhibit 47: F. Hoffmann-La Roche – Organizational developments
Exhibit 48: F. Hoffmann-La Roche – Geographic focus
Exhibit 49: F. Hoffmann-La Roche – Segment focus
Exhibit 50: F. Hoffmann-La Roche – Key offerings
Exhibit 51: F. Hoffmann-La Roche – Key customers
Exhibit 52: Merck Sharp & Dohme – Overview
Exhibit 53: Merck Sharp & Dohme – Business segments
Exhibit 54: Merck Sharp & Dohme – Organizational developments
Exhibit 55: Merck Sharp & Dohme – Geographic focus
Exhibit 56: Merck Sharp & Dohme – Segment focus
Exhibit 57: Merck Sharp & Dohme – Key offerings
Exhibit 58: Merck Sharp & Dohme – Key customers
Exhibit 59: Novartis – Overview
Exhibit 60: Novartis – Business segments
Exhibit 61: Novartis – Organizational developments
Exhibit 62: Novartis – Geographic focus
Exhibit 63: Novartis – Segment focus
Exhibit 64: Novartis – Key offerings
Exhibit 65: Novartis – Key customers
Exhibit 66: Pfizer – Overview
Exhibit 67: Pfizer – Business segments
Exhibit 68: Pfizer – Organizational developments
Exhibit 69: Pfizer – Geographic focus
Exhibit 70: Pfizer – Segment focus
Exhibit 71: Pfizer – Key offerings
Exhibit 72: Pfizer – Key customers
Exhibit 73: Spectrum Pharmaceuticals: Overview
Exhibit 74: Spectrum Pharmaceuticals – Business segments
Exhibit 75: Spectrum Pharmaceuticals – Organizational developments
Exhibit 76: Spectrum Pharmaceuticals – Geographic focus
Exhibit 77: Spectrum Pharmaceuticals – Key offerings
Exhibit 78: Spectrum Pharmaceuticals – Key customers

Companies Mentioned
• F. Hoffmann-La Roche
• Merck Sharp & Dohme
• Novartis
• Pfizer
• Spectrum Pharmaceuticals